Archived AES Symposia 2004
Pediatric Epilepsy State of the Art Symposium
Catastrophic Epilepsy in Infants and Children with Brain Malformations
Program Length: 3 hrs 11 min
The annual Pediatric Epilepsy State of the Art Symposium is devoted to enhancing understanding of epilepsy in children. This year's symposium will address basic science and clinical aspects of hemispheric brain malformations that cause catastrophic epilepsy in infants and children.
At the conclusion of this activity, participants should be able to:
- Understand genetic bases of bilateral hemispheric malformations associated with epilepsy
- Identify predominantly unilateral brain malformations with intractable epilepsy that could be managed surgically
- Learn neuropathological features of brain malformations
- Describe genetic issues and couseling paramount in managing these children and families
- Know future directions and research in this field
Pediatric and adult neurologists, epileptologists, neurosurgeons, neuroscientists, residents/fellows in training, healthcare professionals involved in care of children with epilepsy.
Chair: Elaine Wyllie, M.D.
Co-Chairs: Michael S. Duchowny, M.D., and W. Donald Shields, M.D.
This program and its re-purposing on the AES Web site is supported by an educational grant from UCB Pharma, Inc.
Dr. Chang has indicated that he has no relationships to disclose.
Dr. Gleeson has indicated that he has no relationships to disclose.
Dr. Gupta has indicated having a financial arrangement or affiliation with UCB Pharma.
Dr. Holmes has indicated that he has no relationships to disclose.
Dr. Pellock has indicated that he receives grants/research support in excess of $10,000 and is a paid consultant for Abbott Laboratories, Aventis, Carter Wallace/MedPointe, Cephalon, Elan Pharmaceuticals, Xcel, GlaxoSmithKline, Ortho-McNeil/Johnson & Johnson, Ovation, Pfizer Inc. and UCB Pharma, Inc. Dr. Pellock has no equity, stock or any other ownership interest in any of these companies.
Dr. Sheen has indicated that he has no relationships to disclose.